[13]
Strachan, T.; Read, A.P. Cancer Genetics. Human Molecular Genetics 2nd ed;Wiley-Liss: New York. 1999, pp, 427-444.
[20]
Michael, D. The p53–Mdm2 Module and the Ubiquitin System, Seminars in Cancer Biology; Elsevier; Amsterdam, 2003, pp. 49-58.
[27]
Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. cell, 1992, 69(7), 1237-1245.
[37]
McKean, M.; Tolcher, A.W.; Reeves, J.A.; Chmielowski, B.; Shaheen, M.F.; Beck, J.T.; Orloff, M.M.; Somaiah, N.; Van Tine, B.A.; Drabick, J.J. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. Am. Soc. Clin. Oncol., 2022, 40(16), 9517-9517.
[39]
Kuznar, W. Unique immunotherapy combos evaluated in advanced melanoma. Target Ther Oncol, 2021, 10, 10.
[66]
Pawar, A.C. Targeting p53-MDM2 interaction by natural plant products: A novel approach for future cancer therapy. Int. J. Life Sci. Scienti. Res, 2017, 3(2), 940-950.
[73]
Liu, L.; Xu, Z.; Yu, B.; Tao, L.; Cao, Y. Berbamine inhibits cell proliferation and migration and induces cell death of lung cancer cells via regulating c-Maf, PI3K/Akt, and MDM2-P53 pathways. Evid.-Based Complement. Altern. Med., 2021, 2021, 5517143.
[100]
Chessari, G.; Hardcastle, I.R.; Ahn, J.S.; Anil, B.; Anscombe, E.; Bawn, R.H.; Bevan, L.D.; Blackburn, T.J.; Buck, I.; Cano, C.; Carbain, B.; Castro, J.; Cons, B.; Cully, S.J.; Endicott, J.A.; Fazal, L.; Golding, B.T.; Griffin, R.J.; Haggerty, K.; Harnor, S.J.; Hearn, K.; Hobson, S.; Holvey, R.S.; Howard, S.; Jennings, C.E.; Johnson, C.N.; Lunec, J.; Miller, D.C.; Newell, D.R.; Noble, M.E.M.; Reeks, J.; Revill, C.H.; Riedinger, C.; St Denis, J.D.; Tamanini, E.; Thomas, H.; Thompson, N.T.; Vinković, M.; Wedge, S.R.; Williams, P.A.; Wilsher, N.E.; Zhang, B.; Zhao, Y. Structure-based design of potent and orally active isoindolinone inhibitors of MDM2-p53 protein-protein interaction.
J. Med. Chem., 2021,
64(7), 4071-4088.
[
http://dx.doi.org/10.1021/acs.jmedchem.0c02188] [PMID:
33761253]
[127]
Chessari, G.; Howard, S.; Buck, I. M.; Cons, B. D.; Johnson, C. N.; Holvey, R. S.; Rees, D. C. Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity. Patent US10, 526, 311 B2, 2020.
[128]
Chessari, G.; Howard, S.; Buck, I. M.; Cons, B. D.; Johnson, C. N.; Holvey, R. S.; Rees, D. C. Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity. Patent US10, 981, 898 B2, 2021.
[129]
Ramharter, J.; Broeker, J.; Gille, A.; Gollner, A.; Henry, M.; Kerres, N.; Weinstabl, H. Spiro [3H-indole-3, 2′-pyrrolidin]-2 (1H)-one compounds and derivatives as MDM2-p53 inhibitors. Patent US10, 246, 467 B2, 2019.
[130]
Gollner, A.; Broeker, J.; Kerres, N.; Kofink, C.; Ramharter, J.; Weinstabl, H. Spiro [3H-indole-3, 2′-pyrrolidin]-2 (1H)-one compounds and derivatives as MDM2-P53 inhibitors. Patent US10, 144, 739 B2, 2018.
[131]
Gollner, A.; Broeker, J.; Kerres, N.; Kofink, C.; Ramharter, J.; Weinstabl, H.; Gille, A.; Goepper, S.; Henry, M.; Huchler, G. Spiro [3H-indole-3, 2′-pyrrolidin]-2 (1H)-one compounds and derivatives as MDM2-P53 inhibitors. Patent US10, 882, 866 B1, 2021.
[132]
Chessari, G.; Howard, S.; Buck, I. M.; Cons, B. D.; Johnson, C. N.; Holvey, R. S.; Rees, D. C. Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity. Patent US10, 544, 132 B2, 2020.
[133]
Gollner, A.; Broeker, J.; Kerres, N.; Kofink, C.; Ramharter, J.; Weinstabl, H.; Gille, A.; Goepper, S.; Henry, M.; Huchler, G. Spiro [3H-indole-3, 2′-pyrrolidin]-2 (1H)-one compounds and derivatives as MDM2-P53 inhibitors. Patent US10, 717, 742 B2, 2020.
[134]
Chen, Y.; Ding, Q. J.; Sun, Y.-S. Spiropyrrolidines as MDM2 inhibitors. Patent US9, 701, 685 B2, 2017.
[135]
Weinstabl, H.; Gollner, A.; Ramharter, J.; Wunberg, T. Spiro [3H-indole-3, 2′-pyrrolidin]-2 (1H)-one compounds and derivatives as MDM2-P53 inhibitors. Patent US 10, 576, 064 B2, 2020.
[136]
Gollner, A.; Kofink, C.; Ramharter, J.; Weinstabl, H.; Wunberg, T. Spiro [3H-indole-3, 2′-pyrrolidin]-2 (1H)-one compounds and derivatives as MDM2-P53 inhibitors. Patent US 10 ,138,251 B2, 2018.
[137]
Ramharter, J.; Broeker, J.; Gille, A.; Gollner, A.; Henry, M. New spiro [3h-indole-3, 2´-pyrrolidin]-2 (1h)-one compounds and derivatives as mdm2-p53 inhibitors. Patent EP 3 183 254 B1, 2019.
[138]
Arora, P. S.; Lao, B. B.; Guarracino, D.; Bonneau, R.; Drew, K. Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction. Patent US 11,180,481 B2, 2021.
[139]
Zhang, R.; Wang, W. Cancer treatment utilizing SP-141 to bind with MDM2 and act as an inhibitor of MDM2 expression. Patent US 10,472,355 B2, 2019.
